Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and mAbxience, a majority-owned group by Fresenius Kabi with partial ownership from Insud Pharma, have announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar. This marks the second partnership between the two companies, building on their initial collaboration established in April 2024.
The expanded partnership focuses on developing an additional oncology biosimilar, reinforcing Teva and mAbxience’s shared commitment to delivering cost-effective, high-quality treatments that meet critical needs in oncology. By combining their complementary strengths, the collaboration aims to continue driving innovation and improving access to healthcare solutions for patients worldwide.
The agreement grants Teva exclusive rights for commercialization in multiple regions, including Europe and the United States, aligning with mAbxience’s strategy for global growth. This partnership also supports Teva’s “Pivot to Growth” strategy, expanding its portfolio of biosimilars through targeted partnerships and strategic business development.
As with the initial agreement, mAbxience will take charge of developing and manufacturing the biosimilar at its advanced, cGMP-compliant facilities in Spain and Argentina. Teva will be responsible for managing regulatory approvals and overseeing the commercialization process in key markets, ensuring that patients can access this vital oncology treatment.
Angus Grant, PhD, Executive Vice President of Business Development at Teva, expressed enthusiasm about the strengthened partnership: “This agreement not only deepens our collaboration with mAbxience but also demonstrates our joint commitment to expanding access to critical oncology treatments. It exemplifies Teva’s ideal strategic partnership model—combining development cost optimization, regulatory expertise, and extensive commercial capabilities to provide new treatment options for patients with serious conditions.”
Jurgen Van Broeck, CEO of mAbxience, added, “This second collaboration with Teva, following our initial agreement earlier this year, is a testament to the strength of our partnership and shared vision. We are committed to making high-quality biosimilars accessible and improving healthcare outcomes globally.
